http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 KNOXVILLE, Tenn.--July 17, 2008--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that the... http://pharmalicensing.com/redirs/news_rss//public/news/view/431796/2/provectus-lead-investigator-for-phase-2-melanoma-study-to-address-the-inaugural-sydney-cancer-conference-2008 http://pharmalicensing.com/redirs/news_rss//public/news/view/431796/2/provectus-lead-investigator-for-phase-2-melanoma-study-to-address-the-inaugural-sydney-cancer-conference-2008 LYON, France, July 17, 2008 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that urologists at the University of Texas M.D. Anderson Cancer Center have... http://pharmalicensing.com/redirs/news_rss//public/news/view/431804/2/edap-announces-initial-ablatherm-hifu-treatments-at-premiere-m-d-anderson-cancer-center-in-ongoing-phase-ii-iii-clinical-trial http://pharmalicensing.com/redirs/news_rss//public/news/view/431804/2/edap-announces-initial-ablatherm-hifu-treatments-at-premiere-m-d-anderson-cancer-center-in-ongoing-phase-ii-iii-clinical-trial PORTLAND, Ore.--July 17, 2008-Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free injection therapy systems, today announced that the Biojector® 2000 (B2000) was used... http://pharmalicensing.com/redirs/news_rss//public/news/view/431755/2/biojector-2000-data-presented-in-vical-incorporated-vicl-s-pandemic-influenza-dna-vaccine-human-trial http://pharmalicensing.com/redirs/news_rss//public/news/view/431755/2/biojector-2000-data-presented-in-vical-incorporated-vicl-s-pandemic-influenza-dna-vaccine-human-trial London, UK, and Cambridge, MA, 17 July 2008 - Antisoma plc (LSE:ASM; USOTC: ATSMY) today announced that its Tumour-vascular Disrupting Agent, ASA404, will enter a second pivotal phase III trial this... http://pharmalicensing.com/redirs/news_rss//public/news/view/431767/2/asa404-programme-to-expand-with-new-pivotal-trial-in-lung-cancer http://pharmalicensing.com/redirs/news_rss//public/news/view/431767/2/asa404-programme-to-expand-with-new-pivotal-trial-in-lung-cancer San Antonio, TX, July 17, 2008 -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") today announced that patients with adenocarcinoma (the most frequently occurring form of lung cancer) participating... http://pharmalicensing.com/redirs/news_rss//public/news/view/431749/2/bionumerik-pharmaceuticals-observes-evidence-of-a-survival-increase-in-lung-cancer-patients-participating-in-tavocept-tm-clinical-trial http://pharmalicensing.com/redirs/news_rss//public/news/view/431749/2/bionumerik-pharmaceuticals-observes-evidence-of-a-survival-increase-in-lung-cancer-patients-participating-in-tavocept-tm-clinical-trial Toronto, Ontario - July 17, 2008 - Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today released... http://pharmalicensing.com/redirs/news_rss//public/news/view/431743/2/bradmer-reports-progression-free-survival-data-from-previous-phase-ii-glioblastoma-multiforme-trials http://pharmalicensing.com/redirs/news_rss//public/news/view/431743/2/bradmer-reports-progression-free-survival-data-from-previous-phase-ii-glioblastoma-multiforme-trials AUSTIN, Texas-- July 17, 2008--Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, today announced that the company will present the results from its... http://pharmalicensing.com/redirs/news_rss//public/news/view/431732/2/introgen-to-present-advexin-phase-3-study-results-at-american-association-for-cancer-researchs-cancer-clinical-trials-and-personalized-medicine-conference http://pharmalicensing.com/redirs/news_rss//public/news/view/431732/2/introgen-to-present-advexin-phase-3-study-results-at-american-association-for-cancer-researchs-cancer-clinical-trials-and-personalized-medicine-conference SAN DIEGO, July 17, 2008 -- Vical Incorporated (Nasdaq: VICL) today announced a breakthrough with preliminary clinical trial data demonstrating that DNA vaccines can safely achieve significant immune... http://pharmalicensing.com/redirs/news_rss//public/news/view/431728/2/vical-announces-breakthrough-for-pandemic-influenza-dna-vaccines-with-preliminary-human-data http://pharmalicensing.com/redirs/news_rss//public/news/view/431728/2/vical-announces-breakthrough-for-pandemic-influenza-dna-vaccines-with-preliminary-human-data Freising-Weihenstephan/Jena, Germany, Jul 16, 2008 - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, and Wacker Biotech GmbH, a... http://pharmalicensing.com/redirs/news_rss//public/news/view/431726/2/wacker-validates-scalability-of-anticalin-production-with-e-coli-secretion-technology-and-will-produce-pieris-first-clinical-candidate-prs-050 http://pharmalicensing.com/redirs/news_rss//public/news/view/431726/2/wacker-validates-scalability-of-anticalin-production-with-e-coli-secretion-technology-and-will-produce-pieris-first-clinical-candidate-prs-050 Jerusalem, Israel and Lund, Sweden, July 16, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB (OMX NORDIC: ACTI) announced today that patients are being enrolled for... http://pharmalicensing.com/redirs/news_rss//public/news/view/431208/2/teva-enrolls-patients-for-a-second-large-global-phase-iii-trial-of-oral-laquinimod http://pharmalicensing.com/redirs/news_rss//public/news/view/431208/2/teva-enrolls-patients-for-a-second-large-global-phase-iii-trial-of-oral-laquinimod